| Code | CSB-RA004936MB19HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is developed as a research-grade biosimilar to SEA-CD40, designed for research applications targeting CD40, a member of the tumor necrosis factor receptor superfamily. CD40 is a costimulatory protein expressed on antigen-presenting cells, B cells, and various non-immune cells, playing a critical role in adaptive immunity through interactions with its ligand CD40L. This receptor-ligand pair regulates B cell activation, immunoglobulin class switching, germinal center formation, and dendritic cell maturation. Dysregulation of CD40 signaling is implicated in autoimmune diseases, inflammatory conditions, and cancer, where it can influence tumor immunity and the tumor microenvironment.
SEA-CD40 represents an agonistic antibody designed to activate CD40 signaling pathways, originally developed to enhance anti-tumor immune responses by stimulating dendritic cells and promoting T cell priming. This biosimilar antibody provides researchers with a tool to investigate CD40-mediated immune activation, study costimulatory signaling mechanisms, and explore therapeutic strategies in oncology and immunology research settings. It enables examination of CD40's role in immune cell crosstalk and potential immunotherapeutic applications.
There are currently no reviews for this product.